Suppr超能文献

心得安与吲哚洛尔对病态窦房结综合征窦性心率和起搏频率影响的比较。

Comparison of effects of propranolol versus pindolol on sinus rate and pacing frequency in sick sinus syndrome.

作者信息

Strickberger S A, Fish R D, Lamas G A, Cantillon C, Bhatia S, McGowan N, Antman E M, Friedman P L

机构信息

Cardiac Arrhythmia Service, Brigham and Women's Hospital, Boston, Massachusetts 02115.

出版信息

Am J Cardiol. 1993 Jan 1;71(1):53-6. doi: 10.1016/0002-9149(93)90709-l.

Abstract

Beta blockers in patients with sick sinus syndrome (SSS) may prevent supraventricular arrhythmias, systemic hypertension and myocardial ischemia, but may cause excessive depression of sinus node function. In 8 patients with SSS and a permanent pacemaker, the effect of chronic oral pindolol on sinus rate and pacing frequency was compared with that of propranolol in a double-blind crossover trial. In all patients the pacemaker was programmed to a rate of < or = 50 beats/min. Holter monitors, obtained at baseline and on each drug, were used to calculate peak ambulatory sinus rate, number of paced beats per day, maximal number of paced beats per hour, and percentage of hours with paced beats. The peak sinus rate with pindolol therapy was 24% higher than with propranolol (p = 0.001). During pindolol therapy, the number of paced beats per day and maximal paced beats per hour were reduced 54% (p = 0.04) and 61% (p = 0.02), respectively, compared with propranolol. Patients with SSS who require beta-blocker therapy for tachycardia, systemic hypertension or angina pectoris may have less bradycardia when treated with pindolol rather than propranolol. Beta blockers like pindolol, which cause less sinus node depression, may obviate the need for prophylactic permanent pacemakers in patients with SSS, and may help to prevent chronotropic incompetence and pacemaker syndrome in patients already treated with a VVI device.

摘要

β受体阻滞剂可预防病态窦房结综合征(SSS)患者的室上性心律失常、系统性高血压和心肌缺血,但可能会过度抑制窦房结功能。在一项双盲交叉试验中,对8例患有SSS且植入永久起搏器的患者,比较了慢性口服吲哚洛尔与普萘洛尔对窦性心率和起搏频率的影响。所有患者的起搏器均程控为心率≤50次/分钟。在基线及每种药物治疗时使用动态心电图监测仪,以计算动态窦性心率峰值、每日起搏次数、每小时最大起搏次数以及起搏的小时数百分比。吲哚洛尔治疗时的窦性心率峰值比普萘洛尔治疗时高24%(p = 0.001)。与普萘洛尔相比,在吲哚洛尔治疗期间,每日起搏次数和每小时最大起搏次数分别减少了54%(p = 0.04)和61%(p = 0.02)。对于因心动过速、系统性高血压或心绞痛而需要β受体阻滞剂治疗的SSS患者,使用吲哚洛尔治疗时的心动过缓可能比使用普萘洛尔时少。像吲哚洛尔这样引起较少窦房结抑制的β受体阻滞剂,可能使SSS患者无需预防性植入永久起搏器,并可能有助于预防已接受VVI装置治疗的患者出现变时性功能不全和起搏器综合征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验